Abstract
Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases. Here we identify indirubin and its analogues as potent inhibitors of cyclin-dependent kinases (CDKs). The crystal structure of CDK2 in complex with indirubin derivatives shows that indirubin interacts with the kinase’s ATP-binding site through van der Waals interactions and three hydrogen bonds. Indirubin-3′-monoxime inhibits the proliferation of a large range of cells, mainly through arresting the cells in the G2/M phase of the cell cycle. These results have implications for therapeutic optimization of indigoids.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zhu, Y.-P. & Woerdenbag, H. J. Traditional Chinese herbal medicine. Pharm. World Sci. 17, 103– 112 (1995).
Tang, W. & Eisenbrand, G. Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine (Springer, Heidelberg, 1992).
Han, R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 12, 53–63 ( 1994).
Chinese Pharmacopoeia Vol. 1 (People’s Health Publisher, Beijing, 1995).
Clinical studies of Dang Gui Lu Hui Wan in the treatment of CML. Chinese J. Intern. Med. 15, 86– 88 (1979).
Wu, L. M., Yang, Y. P. & Zhu, Z. H. Studies on the active principles of indigofera tinctoria in the treatment of CML. Comm. Chinese Herb. Med. 9 , 6–8 (1979).
Wu, G. Y., Fang, F. D., Liu, J. Z., Chang, A. & Ho, Y. H. Studies on the mechanism of action of indirubin in the treatment of chronic granulocytic leukemia. I. Effects on nucleic acid and protein synthesis in human leukemic cells. Chinese Med. J. 60, 451–454 (1980).
Zheng, Q. T., Lu, D. J. & Yang, S. L. Pharmacological studies of indirubin. I. Antitumor effect . Comm. Chinese Herb. Med. 10, 35– 39 (1979).
Zheng, Q. T., Qi, S. B. & Cheng, Z. Y. Pharmacological studies of indirubin. II. Absorption, distribution and excretion of 3H-indirubin. Comm. Chinese Herb. Med. 10, 19–21 (1979).
Zhang, S. X. Studies on the chemical constituents of Isatis indigotica root. Chinese Trad. Herb. Drugs 14, 247– 248 (1983).
Chen, D. H. & Xie, J. X. Chemical constituents of traditional Chinese medicine Qing Dai. Chinese Trad. Herb. Drugs 15, 6–8 (1984).
Hurry, J. B. The Woad Plant and its Dye (Oxford Univ. Press, Oxford, 1930).
Balfour-Paul, J. Indigo (British Mus. Press, London, 1998).
Chang, H. M. & But, P. P. H. Pharmacology and Applications of Chinese Materia Medica Vol. 2 (ed. Teaneck, N.J.) (World Scientific Pub. Co., Singapore, 1987).
Zhang, L., Wu, G. Y. & Qiu, C. C. Effect of indirubin on DNA synthesis in vitro. Acta Acad. Med. Sin. 7, 112–116 (1985).
Du, D. J. & Ceng, Q. T. Effect of indirubin on the incorporation of isotope labeled precursors into nucleic acid and protein of tumor tissues . Chinese Trad. Herb Drugs 12, 406– 409 (1981).
Wu, G. Y., Liu, J. Z., Fang, F. D. & Zuo, J. Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. V. Binding between indirubin and DNA and identification of the type of binding . Sci. Sin. 25, 1071–1079 (1982).
Lee, K. et al. Ultrastructural study on the mechanism of the therapeutic effect of indirubin for human chronic granulocytic leukemia. Natl Med. J. China 59, 129–132 ( 1979).
Ji, X. J., Zhang, F. R., Lei, J. L. & Xu, Y. T. Studies on the antineoplastic effect and toxicity of synthetic indirubin. Acta Pharma. Sin. 16, 146–148 (1981).
Wang, J. H., You, Y. C., Mi, J. X. & Ying, H. G. Effect of indirubin on hematopoietic cell production. Acta Pharmacol. Sin. 2, 241–244 (1981).
Sichuan Institute of Traditional Chinese Medicine . Subacute toxicity of indirubin in dogs. Chinese Trad. Herb Drugs 12, 27–29 (1981).
Ji, X. J. & Zhang, F. R. Antineoplastic effect of indirubin derivatives and their structure-activity relationship. Acta Pharm. Sin. 20, 137–139 ( 1985).
Gu, Y. C., Li, G. L., Yang, Y. P., Fu, J. P. & Li, C. Z. Synthesis of some halogenated indirubin derivatives. Acta Pharm. Sin. 24, 629–632 (1989).
Ji, X. J., Liu, X. M., Li, K., Chen, R. H. & Wang, L. G. Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomed. Environm. Sci. 4, 332–337 (1991).
Li, C. et al. The synthesis, antileukemic activity, and crystal structures of indirubin derivatives. Bull. Chem. Soc. Jpn 69, 1621–1627 (1996).
Wu, K. M., Zhang, M. Y., Fang, Z. & Huang, L. Potential antileukemic agents, synthesis of derivatives of indirubin, indigo and isoindigotin. Acta Pharm. Sin. 20, 821–826 (1985).
Chang, C. N. in Advances in Chinese Medicinal Materials Research (eds Chang, H. M., Yeung, H. W., Tso, W., Koo, A.) 369–376 (World Scientific Pub. Co., Singapore, 1985).
Wan, J. H., You, Y. C., Mi, J. X. & Ying, H. G. Effect of indirubin on hematopoietic cell production. Acta Pharmacol. Sin. 2, 241–244 (1981).
Experimental and clinical studies of indirubin in the treatment of CML. Chinese J. Intern. Med. 18 , 83–88 (1979).
Clinical studies of 314 cases of CML treated with indirubin . Chinese J. Intern. Med. 1, 132– 135 (1980).
Gan, W. J. et al. Studies on the mechanism of indirubin action in treatment of chronic myelocytic leukemia (CML). II. 5"-Nucleotidase in the peripheral white blood cells of CML. Chinese J. Hematol. 6, 611–613 (1985).
Zhang, Z. N. et al. Treatment of chronic myelocytic leukemia (CML) by traditional Chinese medicine and Western medicine alternatively. J. Trad. Chinese Med. 5, 246–248 ( 1985).
Ma, M. & Yao, B. Progress in indirubin treatment of chronic myelocytic leukaemia. J. Trad. Chinese Med. 3, 245–248 (1983).
Jiang, S.Z. et al. Adverse effects of indirubin on cardiovascular system. Chinese J. Hematol. 7, 30 (1986 ).
Morgan, D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13, 261– 291 (1997).
Meijer, L. & Kim, S. H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283, 113– 128 (1997).
Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 . Eur. J. Biochem. 243, 527– 536 (1997).
Schulze-Gahmen, U. et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins Struct. Funct. Genet. 22, 378–391 ( 1995).
De Azevedo, W. F. et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl Acad. Sci. USA 93, 2735–2740 ( 1996).
De Azevedo, W. F. et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518–526 (1997).
Gray, N. et al. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 281, 533–538 (1998).
Lawrie, A. M. et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 4, 796–800 (1997).
De Bondt, H.L. et al. Crystal structure of cyclin-dependent kinase 2. Nature 363, 595–602 ( 1993).
Russo, A., Jeffrey, P. D. & Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struct. Biol. 3, 696–700 (1996).
Knighton, D.R. et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 414–420 ( 1991).
Brown, N. R. et al. Effects of phosphorylation of threonine 160 on CDK2 structure and activity. J. Biol. Chem. (in the press).
Otwinowski, Z. in Oscillation Data Reduction Program (eds Sawyer, L., Isaacs, N. & Bailey, S.) 56– 62 (SERC Lab., Daresbury, Warrington, UK, 1993).
The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760–763 ( 1994).
Acknowledgements
We thank N. Xiuren for his help with Chinese ideogram; the fishermen of the Station Biologique de Roscoff for collecting the starfish; D. Alessi, M. Cobb, W. Harper, F. Hofmann, J. Lahti, S. Lohmann, H. Mett, D. Morgan, L. Pinna and H. Y. L. Tung for providing reagents and purified enzymes; D. Louvard, M. Mareel, M. Crepin and J.P. Moulinoux for providing cell lines; the scientists at the X-ray diffraction beamline, Elettra, Trieste; W. Burmeister for assistance during data collection on ID14-3 at the ESRF; and S. Lee, R. Bryan, K. Measures and I. Taylor for assistance. This research was supported by grants from the Association pour la Recherche sur le Cancer and the Conseil Régional de Bretagne (to L.M.), from the BBSRC, MRC and the Royal Society (to J.A.E. and M.E.M.N.) and from the German Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (to G.E.).
Correspondence and requests for materials should be addressed to L.M. or G.E.
Supplementary Information is available on Nature Cell Biology’s World-Wide Web site (http://cellbio.nature.com) or as paper copy from the London editorial office of Nature Cell Biology.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Hoessel, R., Leclerc, S., Endicott, J. et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1, 60–67 (1999). https://doi.org/10.1038/9035
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/9035
This article is cited by
-
Indigofera suffruticosa aerial parts extract induce G2/M arrest and ATR/CHK1 pathway in Jurkat cells
BMC Complementary Medicine and Therapies (2024)
-
Development of a novel indirubin derivative with enhanced anticancer properties: synthesis, in Vitro, and in Vivo evaluation
Chemical Papers (2024)
-
Targeting CDK1 in cancer: mechanisms and implications
npj Precision Oncology (2023)
-
Structure-guided engineering of a flavin-containing monooxygenase for the efficient production of indirubin
Bioresources and Bioprocessing (2022)
-
Synergistic effect of plasma-activated medium and novel indirubin derivatives on human skin cancer cells by activation of the AhR pathway
Scientific Reports (2022)